LEXINGTON, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced the relocation of its company headquarters to Lexington, MA. The new facilities include significant laboratory space, which will expand discovery and translational research capabilities as the Company further develops its rare disease pipeline and advances its lead program, SBC-102. SBC-102 is an enzyme replacement therapy to treat Lysosomal Acid Lipase (LAL) Deficiency, also known as Wolman Disease or Cholesteryl Ester Storage Disease (CESD).
